Key points from article :
Oxford Biomedica, a leading UK-based biotech company, has reported strong momentum for the first half of 2024, projecting revenues of around £50 million. The firm expects full-year revenues to reach between £126 million and £134 million, reflecting its strategic transition from COVID-19 vaccine manufacturing to becoming a specialist contract development and manufacturing organisation (CDMO) in cell and gene therapy.
The company has recently streamlined operations across the UK, US, and Europe, including the acquisition of ABL Europe—now renamed Oxford Biomedica (France). These efforts are aimed at increasing efficiency and strengthening its position in the competitive advanced therapies market.
CEO Dr. Frank Mathias highlighted the company's growing order book and high reservation rates for GMP (Good Manufacturing Practice) facilities in 2025 as signs of sustained demand. He noted that their "multi-site, multi-vector strategy" is showing results, boosting confidence in Oxford Biomedica’s growth trajectory in the expanding cell and gene therapy sector.
The company is expected to release its full interim results on 23 September 2024.
